Please login to the form below

Not currently logged in


This page shows the latest mRNA news and features for those working in and with pharma, biotech and healthcare.

Moderna CEO makes case for firm’s lofty valuation

Moderna CEO makes case for firm’s lofty valuation

mRNA specialist has to convince investors after stocks slide. Moderna CEO Stéphane Bancel took the stage at the JP Morgan Healthcare conference yesterday to give an update on the firm’s ... Moderna’s specialty is in messenger RNA (mRNA) drugs which

Latest news

More from news
Approximately 1 fully matching, plus 22 partially matching documents found.

Latest Intelligence

  • Gene therapy Gene therapy

    These early pioneers were largely focused on DNA-based gene delivery or the use of DNA anti-sense technologies to specifically inhibit mRNA translation. ... From a payload perspective, these include new technologies such as siRNA, Sleeping Beauty

  • Deal Watch March 2017 Deal Watch March 2017

    In our Top 20 we have only three: Alexion in-licensed the lipid nanoparticle (LNP) technology from Arbutus Biopharma to use as a delivery technology for an mRNA rare disease product

  • Deal Watch September 2016 Deal Watch September 2016

    At a lower disclosed headline value of $310m BioNTech licensed its mRNA-based cancer vaccines platform to Genentech. ... Licence. mRNA personalised cancer vaccines; $310m upfront and near-term payments. 310+.

  • Deal Watch June 2016 Deal Watch June 2016

    The mRNA vaccines will also be assessed in combination with Keytruda on an exclusive basis. ... licence. 230. Moderna Therapeutics/ Merck &Co. mRNA-based personalised cancer vaccines; exclusive for Keytruda combinations (discovery).

  • Deal Watch November 2015 Deal Watch November 2015

    Sanofi will gain access to BioNTech's mRNA formulation technology to generate new cancer immunotherapies. ... Discover/ develop up to 5 cancer immunotherapies, each a synthetic mRNA mixture.

More from intelligence
Approximately 0 fully matching, plus 12 partially matching documents found.

Latest appointments

  • CureVac’s CEO appointed to EC High Level Group CureVac’s CEO appointed to EC High Level Group

    Dr Ingmar Hoerr, chief executive officer of clinical-stage mRNA technology specialist CureVac, has been appointed to the European Commission's High Level Group for research and innovation programmes. ... As one of the pioneering companies in mRNA

  • CureVac appoints chief financial officer CureVac appoints chief financial officer

    Pierre Kemula joins the mRNA company’s management board. Tübingen, Germany-based mRNA firm CureVac has appointed Pierre Kemula as its new chief financial officer. ... accomplishment for CureVac as the company prepares for multiple near-term corporate

  • Dr Michael Watson appointed as president of Valera Dr Michael Watson appointed as president of Valera

    Dr Watson said: “The potential for mRNA therapeutics to meaningfully address some of the world's most pressing infectious disease concerns is truly exciting.

More from appointments
Approximately 0 fully matching, plus 3 partially matching documents found.

Featured jobs

Subscribe to our email news alerts


Add my company
Syneos Health™

Syneos Health™ is the only fully integrated biopharmaceutical solutions organization. Our company, including a Contract Research Organization (CRO) and Contract...

Latest intelligence

50 questions for delivering an exceptional healthcare brand experience
Our 50-question brand planning checklist for healthcare ensures you deliver an exceptional experience, based on what your stakeholders want and need...
The brand strategy revolution
Introducing a new tool for developing a stakeholder-centric brand, based on the experience your patients and their HCPs want and need....
How Medisafe is using AI to improve patient adherence
Dina Patel speaks to Omri Shor, Co-Founder and CEO of Medisafe, to find out how his medication management app is tackling the problem of poor adherence....